An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of NTKR-214 in combination with nivolumab in Japanese participants with advanced malignant tumors.
Advanced Cancer
BIOLOGICAL: NKTR-214|BIOLOGICAL: Nivolumab
Incidence of adverse events (AEs), Approximately 2 years|Incidence of serious adverse events (SAEs), Approximately 2 years|Incidence of AEs leading to discontinuation, Approximately 2 years|Incidence of deaths, Approximately 2 years|Incidence of AEs meeting protocol-defined dose limiting toxicity (DLT) criteria, Approximately 2 years|Incidence of laboratory abnormalities, Approximately 2 years
Maximum observed concentration (Cmax), Approximately 2 years|Time of maximum observed concentration (Tmax), Approximately 2 years|Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)], Approximately 2 years|Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)], Approximately 2 years|Total body clearance (CLT), Approximately 2 years|Volume of distribution (Vz), Approximately 2 years|Apparent terminal phase half-life (T-HALF), Approximately 2 years|Trough observed serum concentration at the end of the dosing interval (Ctrough), Approximately 2 years|Incidence of anti-drug antibodies (ADA) to NKTR-214, Approximately 2 years|Incidence of anti-drug antibodies (ADA) to nivolumab, Approximately 2 years|Best overall response (BOR), Approximately 2 years|Duration of response (DOR), Approximately 2 years
The purpose of this study is to assess the safety and tolerability of NTKR-214 in combination with nivolumab in Japanese participants with advanced malignant tumors.